Study of the effect of hyperbaric oxygen therapy on the bacteria in chronic wounds

1 1 1 1

What is this study about?

This study focuses on individuals living with chronic wounds, which are sores that do not heal within the expected timeframe. The research aims to evaluate the impact of hyperbaric oxygen therapy, a method where a person breathes oxygen through a specialized breathing tube while inside a pressurized chamber, on the types of bacteria living in these wounds. These bacteria are part of the wound microbiome, which refers to the collection of tiny living organisms that inhabit the area around and inside the wound.

Participants will undergo a period of treatment lasting six weeks. During this time, the effects of the pressurized oxygen on the wound’s environment and the healing process will be observed. The study will look at how the different types of microorganisms in the wound change and how this influences the body’s ability to repair the tissue and reduce the size of the sore.

Who Can Join the Study?

  • You must be 18 years of age or older.
  • You must have a chronic wound, which is a sore or injury that has not healed after more than one month of regular medical treatment. Examples include diabetic ulcers (sores caused by diabetes), vascular ulcers (sores caused by issues with blood flow), or pressure ulcers (sores caused by prolonged pressure on the skin).
  • You must be willing and able to complete at least 30 sessions of Hyperbaric Oxygen Therapy (HBOT), which is a treatment where you breathe pure oxygen in a pressurized chamber, over a period of 6 weeks.
  • You must be healthy enough to undergo Hyperbaric Oxygen Therapy (HBOT) based on standard medical safety checks.
  • You must provide informed consent, which means you agree to take part in the study after understanding all the details and risks.

Who Cannot Join the Study?

  • You are currently taking part in another clinical trial (a research study involving people) that affects how wounds heal or the microbiome (the collection of tiny organisms like bacteria living on the body).
  • You have acute wounds (new or sudden injuries) or wounds caused by infectious diseases, such as osteomyelitis (an infection in the bone), that were not specifically allowed for this study.
  • You have medical reasons why you cannot receive Hyperbaric Oxygen Therapy (a treatment where you breathe pure oxygen in a pressurized chamber), such as an untreated pneumothorax (a collapsed lung) or severe claustrophobia (an extreme fear of being in small, enclosed spaces).
  • You have conditions that affect your immune function (your body’s ability to fight off germs), such as an active case of HIV/AIDS or if you are currently receiving chemotherapy (medicine used to treat cancer).
  • You are currently pregnant or breastfeeding.
  • You are currently using the medication disulfiram (brand name Antabuse®), because it may interfere with how your body handles oxygen and could increase the risk of oxygen toxicity (harm caused to the body by breathing too much oxygen).

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Medical University Of Graz Graz Austria

Other Sites

No sites found in this category

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Austria Austria
Recruiting
01.12.2025

Trial locations

Investigated drugs:

Oxygen therapy is used in this study to see how breathing in compressed medical oxygen in a pressurized chamber can help change the types of bacteria living in a chronic wound and help the wound heal better.

Chronic wounds – These are sores or injuries that fail to heal through the normal biological process within a typical timeframe. They often result from ongoing inflammation or issues with blood flow and tissue repair. As the condition progresses, the skin and underlying tissues may experience persistent damage. This delay in healing can allow various microorganisms to settle in the area. The presence of these microbes can further alter the natural healing environment.

Trial ID:
2025-523863-39-00
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Verteporfin for Scar Prevention in Patients After Surgical Wounds

    Not yet recruiting

    1 1
    Investigated drugs:
    Denmark
  • Safety, tolerability and efficacy of topical human fibroblasts in patients with chronic refractory wounds (two-part study)

    Not yet recruiting

    1 1
    Investigated drugs:
    Italy